

Qty: 100μg/400 μL Rabbit anti-PDEF For Research Use Only **Catalog No.** 36-3600 Lot No.

Rabbit anti-PDEF

FORM

This polyclonal antibody is supplied as a 400 µL aliquot at a concentration of 0.25 mg/mL in phosphate buffered saline (pH 7.4) containing 0.1% sodium azide. This antibody is epitope-affinity purified from rabbit antiserum.

PAD: ZMD.299

IMMUNOGEN

Synthetic peptide derived from the internal region of human PDEF (prostate-derived Ets factor).

SPECIFICITY

This antibody is specific for human PDEF. On Western blots, it identifies a single band at ~37.5 kDa using LNCAP lysates. There is also a weak band at ~55 kDa which may be due to the glycosylated form of PDEF.

REACTIVITY

Reactivity has been confirmed with human LNCAP prostate carcinoma cell lysates.

Sample	Western Blotting	ELISA
Human	+++	ND
Immunogen	N/A	+++

(Excellent +++, Good++, Poor +, No reactivity 0, Not applicable N/A, Not Determined ND)

USAGE

Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

ELISA: 0.1-1μg/mL Western Blotting: 1-3 μg/mL

STORAGE

Store at 2-8°C for up to one month. Store at -20°C for long-term storage. Avoid repeated freezing and thawing.

(cont'd)

(36-3600 cont'd)

BACKGROUND

PDEF (prostate-derived Ets factor) is a 37.5-kDa protein that acts as an androgen-independent transcriptional activator for the PSA (prostate specific antigen) promoter. It also interacts directly with the DNA binding domain of androgen receptor and enhances androgen-mediated activation of the PSA promoter¹. PDEF was shown to have transcript levels 192-fold higher in the peripheral blood of some breast cancer patients in comparison with normal individuals². PDEF mRNA is also frequently over-expressed in human breast tumors as well as in human ovarian tumors. In ovarian tumors, PDEF expression seems to down-modulate malignant potential, and thus provides a rationale to screen for drugs that induce PDEF expression in epithelial ovarian tumors³.

REFERENCES

- 1. Oettgen P et al., 2000. J Biol Chem 275(2):1216-1225, 2000.
- 2. Ghaderoshi A, Sood AK. Clin Cancer Res 7(9):2731-2738, 2001.
- 3. Ghaderoshi A et al. Front Biosci 7:e48-57, 2002.

RELATED PRODUCTS

Product	Clone/PAD*	Cat. No.
Rabbit anti-PSMA ("C-term")	ZMD.80	34-4100
Rabbit anti-PSMA ("N-term")	ZMD.31	34-3200
Rabbit anti-PTEN	EC8	51-7800
Mouse anti-PSA	Z009	18-0044
Protein A	Sepharose [®] 4B	10-1041
rec-Protein G	Sepharose [®] 4B	10-1241
*PAD: Polyclonal Antibody Designation		

Conjugate	ZyMAX™ Goat x Rabbit IgG (H+L)	ZyMAX™ Goat x Mouse IgG (H+L)
Purified	81-6100	81-6500
FITC	81-6111	81-6511
TRITC	81-6114	81-6514
Су™3	81-6115	81-6515
Cy™5	81-6116	81-6516
HRP	81-6120	81-6520
AP	81-6122	81-6522
Biotin	81-6140	81-6540

Zymed[®] and ZyMAX[™] are trademarks of Zymed Laboratories Inc. Cy[™] and Sepharose[®] are trademarks of Amersham Biosciences Ltd.

For Research Use Only

JT030710

(Rev 10/08) DCC-08-1089

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI363600

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, <u>www.invitrogen.com</u>). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.